The main purpose of this study is to assess two formulations of LY3819469 based on the amount that gets into the blood stream and how long it takes the body to get rid of it, when given to healthy participants. The information about any adverse effects experienced will be collected and the tolerability of LY3819469 will also be evaluated. Screening is required within 28 days prior to the enrolment. For each participant, the total duration of the clinical trial will be about 17 weeks including screening and follow-up periods.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Enrollment
27
Administered SC.
Lilly Centre for Clinical Pharmacology
Singapore, Singapore
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to the Last Timepoint with Measurable Concentration (AUC[0-tlast]) of LY3819469
PK: AUC\[0-tlast\] of LY3819469
Time frame: Predose on day 1 up to postdose on day 85
PK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-∞]) of LY3819469
PK: AUC\[0-∞\] of LY3819469
Time frame: Predose on day 1 up to postdose on day 85
PK: Maximum Observed Concentration (Cmax) of LY3819469
PK: Cmax of LY3819469
Time frame: Predose on day 1 up to postdose on day 85
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.